Learn more about the Accelerator- READ OUR WHITE PAPER
Annual Program Impact
While traditional healthcare startups face a staggering 97% failure rate, CancerX Accelerator companies are rewriting the success story. Through our specialized ecosystem connecting startups with leading health systems, payors, and technology enterprises, we're accelerating the journey from laboratory breakthrough to patient bedside.
Scaling The Impact
Building on the inaugural cohort's momentum, our 2025 program demonstrated exceptional engagement and partnership development. The quality of relationships and collaborative opportunities reached new heights, with startups forging connections across multiple sectors—from pharmaceutical companies to health systems.
2025 Accelerator Alumni
Meet the 14 finalists driving innovation in last year's cohort
2025 Accelerator Impact
.png?width=1920&height=1080&name=accelerator%20impact%20graphics%20(1).png)
“Bringing new cancer technology to market is hard, but fighting cancer is harder. At CancerX, everyone came together with urgency, patient focus, and a deep understanding of cancer’s impact on the entire family. Doctors, advocates, hospital networks, insurers, pharma, and investors united in one ecosystem, committed to transforming cancer care for all.”
Jim Foote
CEO, First Ascent
"We found the CancerX Accelerator program as a whole to be incredibly valuable. The depth of support and expertise available through the network has accelerated our growth in ways we couldn't have imagined."
Eirini Schlosser
CEO, Dyania Health
"The networking opportunities, exposure to industry leadership, and hands-on support from our champions - that combination was the most valuable part of the entire program. It's given us connections that will benefit our company for years to come."
Eric Horler
AIQ Solutions
2025 Transformational Success Stories
First Ascent Biomedical exemplifies the power of perseverance and program growth. After rejection from the 2024 cohort, they returned stronger and transformed multiple champion relationships into concrete opportunities. During the accelerator, they launched a multi-site feasibility study enrolling 200 pediatric, adolescent, and young adult cancer patients across a national network, secured a $2 million grant from the Florida Cancer Innovation Fund, and won the People's Choice Award—completing a remarkable journey from rejection to recognition.
Manta Cares entered with momentum in pharmaceutical partnerships but used the CancerX program to expand far beyond their initial scope. Through the accelerator's curated mentorship network, they developed crucial relationships with payer organizations that evolved into concrete business opportunities. The exclusive CancerX events enabled them to forge meaningful relationships with health systems, resulting in multiple co-development and pilot opportunities spanning various disease areas beyond cancer care. They also won two prestigious patient experience-focused awards during the program.
We Are Here set a new speed record in CancerX accelerator history by launching a pilot program before the end of their cohort—demonstrating exceptional execution capabilities. They leveraged this record-breaking launch to systematically scale their impact, immediately using results and learnings from their initial health system implementation to design a second pilot. Their dual-user platform serving both social workers and patients provided critical insights about operational workflows and impact measurement.
Proving The Model
Our inaugural cohort demonstrated that specialized healthcare innovation programs dramatically outperform traditional approaches. While generic accelerators often prioritize investment readiness above all else, CancerX took a comprehensive approach—emphasizing implementation pathways, clinical validation, and deep relationship-building alongside financial success.
2024 Accelerator Alumni
Meet the finalists driving innovation in the inaugural cohort
2024 Accelerator Impact
.png?width=1920&height=1080&name=accelerator%20impact%20graphics%20(2).png)
“Our business model uses AI for summarization and second opinions. We didn’t think the process we built out to assist with our final goal (retrieving and organizing medical records quickly and meaningfully) was the piece that made all the difference to Moffitt. Because of the CancerX Accelerator, we are thrilled to have our product tested out to solve for record retrieval, something we previously have not pursued uniquely. The way Moffitt as a health system framed their use cases achieves outcomes we hadn’t thought of and expands use cases our product can make an impact for. It is also equally exciting that Moffitt and Navya are learning together about how best to leverage AI, and I think we will emerge stronger together.”
Naresh Ramarajan
MD. Chief Medical Officer, Navya
“2024 Accelerator ImpactThe Atrium Health team has been an outstanding development partner and champion for us at Lind during the CancerX accelerator. Over the past six months, their unparalleled commitment of time, expertise, and access to over 50 clinicians has truly demonstrated Atrium’s dedication to innovation. Throughout our collaboration, consistent themes have emerged—Atrium’s compassionate patient-first approach, commitment to delivering exceptional care, drive for safe innovation, and remarkable clinical expertise have truly set them apart. We at Lind are deeply grateful for the support we’ve received and look forward to continuing our partnership to offer every patient access to clinical trials as part of their care journey, by reducing the operational challenges of trial matching and discovery.”
Oggie Nikolic
CEO, Lind
“We are excited to pilot our AI-driven clinical workflow technology at Moffitt Cancer Center as part of the CancerX Accelerator’s inaugural cohort. We appreciate the opportunity to pilot our technology in a real world clinical setting to evaluate its impact on clinical efficiency, operational excellence and patient experience. Moffitt’s leadership in being an early evaluator and adopter is key to a sustainable and scalable healthcare innovation.”
Tarun Kumar
Co-Founder and CEO, Cancer Insights
2024 Transformational Success Stories
Navya Network leverages AI and machine learning to develop personalized cancer treatment plans. Their accelerator journey culminated in a moment of serendipitous validation at the graduation reception when Dr. Wu enthusiastically praised their solution to colleagues while the founder happened to be standing nearby, prompting a "That's my solution!" moment of recognition. They've secured two deals in progress with their champion, Moffitt Cancer Center.
Navya Network leverages AI and machine learning to develop personalized cancer treatment plans. Their accelerator journey culminated in a moment of serendipitous validation at the graduation reception when Dr. Wu enthusiastically praised their solution to colleagues while the founder happened to be standing nearby, prompting a "That's my solution!" moment of recognition. They've secured two deals in progress with their champion, Moffitt Cancer Center.
Navya Network leverages AI and machine learning to develop personalized cancer treatment plans. Their accelerator journey culminated in a moment of serendipitous validation at the graduation reception when Dr. Wu enthusiastically praised their solution to colleagues while the founder happened to be standing nearby, prompting a "That's my solution!" moment of recognition. They've secured two deals in progress with their champion, Moffitt Cancer Center.